It has been hypothesized that a subgroup of patients with a worse prognosis may benefit from the addition of an MEK inhibitor, particularly those with a higher BRAF-mutant allele fraction in circulating tumor DNA31 or tumor tissue,13 or those classified under the CMS4 or BM1 subgroups based on transcriptome analysis.32 This evidence concerns the gene MAP2K7 and neoplasm.